BeiGene Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fifth FDA approval, BRUKINSA now has the broadest label in the BTKi class Rapidly advancing late-stage hematology pipeline; sonrotoclax in development both as a monotherapy and in combination with backbone therapy BRUKINSA; pivotal program initiated for BTK CDAC Progressing potentially differentiated solid tumor programs with ADC, degrader platforms and targeted therapies in priority cancer types Significantly improved operating leverage and progress on path to sustainable profitability SAN MATEO, Calif., May 08, 2024 BUSINESS WIRE BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the first quarter 2024 and business highlights. "We are pleased to present another quarter of strong financial results. Supported by our tremendous global growth in revenue, we have now ascen
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Denmark Pharmaceutical Market size is set to grow by USD 852.1 mn from 2024-2028, high investment in pharmaceutical industry to boost the market growth, Technavio [Yahoo! Finance]Yahoo! Finance
- AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® [Yahoo! Finance]Yahoo! Finance
- AbbVie Inc. (NYSE: ABBV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $200.00 price target on the stock.MarketBeat
- AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®PR Newswire
- Non Hodgkin Lymphoma (NHL) Global Market Report 2024: Asia-Pacific Set for Swift Growth Amidst Advancements in Immunotherapy and Diagnostic Tools [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 5/17/24 - Form 25-NSE
- 5/8/24 - Form 8-K/A
- 5/7/24 - Form 4
- ABBV's page on the SEC website